The need for comprehensive studies of cGVHD/Scl models to develop improved translational therapeutics is highlighted, with two distinct murine alloHSCT model in which hosts were lethally irradiated and given bone marrow ± T cells to induce cGVHD.
Christina Hartigan, Brent H. Koehn, Cameron McDonald Hyman et al.· Journal of Immunology· 0 citations
The findings suggest that CAR19 Tregs represent a promising and safe cGVHD/BOS therapeutic strategy, offering immunosuppressive benefits and improved disease outcomes that may be more limited with CD8+ CAR19 T cell treatment.
Sujeong Jin, Michael C. Zaiken, Cameron McDonald-Hyman et al.· JCI Insight· 0 citations
Efficient generation of iDC3s is demonstrated, their developmental trajectory, and regulatory potential are defined, and how DC3s operate across disease contexts are revealed, revealing how DC3s operate across disease contexts.
Jordan Fink, Ke Yao, Lie Ma et al.· Journal of Immunology· 0 citations
The clinical successes of chimeric antigen receptor (CAR) T cells represent a major shift in immunotherapy. However, there is also increasing emphasis on potential long-term effects of CAR T cell therapy, especially using preclinical xenogeneic models. It has been previously demonstrated that only naïve, and not memory...
Wahed A. Firoz, Michael K. Sheng, Pedro Ruivo et al.· Blood Advances· 0 citations
Genetic Id2 loss uncouples Tfh differentiation from effector activity, positioning Id2 inhibition as a novel therapeutic strategy to selectively disrupt pathogenic Tfh-GCB crosstalk in cGVHD.
Yujie Zhao, Eun Ko, Cameron McDonald-Hyman et al.· Journal of Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
